IP Library Granted Patent US 11,253,513
Granted Patent B2
US 11,253,513 · App. 16/594,919 · Granted Feb 22, 2022

Dosing regimen for injectable cetirizine

Inventor: Jie Du (Lansdale, PA)
Assignee: JDP THERAPEUTICS LLC
A61K31/495A61K9/0019A61P17/04A61P37/08
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,253,513
App. No.
16/594,919
Granted
Feb 22, 2022
Kind
B2
Abstract

Described herein is a method of administering injectable cetirizine or levocetirizine including intravenously injecting a mammal in need thereof with a therapeutically effective amount of an injectable cetirizine or levocetirizine composition, wherein the mammal receives a maximum daily dose of the cetirizine or levocetirizine that is no more than 15 times a maximum recommended daily clinical dose for the mammal.

Claims (10)

1. A method of administering injectable cetirizine or levocetirizine to a human subject, comprising intravenously injecting the human subject subject in need thereof with an intentional or an unintentional overdose of a maximum daily dose of the cetirizine or levocetirizine,

wherein the human subject is a child 6 months to 5 years and the maximum human daily clinical dose of cetirizine dihydrochloride is 2.5 mg; the human subject is a child 6 to 11 years and the maximum human daily clinical dose of cetirizine dihydrochloride is 5 to 10 mg; or the human subject is an adult of adolescent 12 years older and the maximum daily clinical dose of cetirizine dihydrochloride is 10 mg.

2. The method of claim 1 , wherein the human subject is suffering from acute urticaria.

3. The method of claim 2 , wherein the human subject has concomitant angioedema.

4. The method of claim 1 , wherein the injectable composition is a 10 mg/mL aqueous cetirizine dihydrochloride solution.

5. The method of claim 1 , wherein the administering occurs in an emergency department or in an urgent care center.

6. The method of claim 1 , wherein the overdose is 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14 times the maximum recommended daily clinical dose for the mammal.

7. The method of claim 1 , wherein the overdose is an overdose administered, prescribed by, or suggested by a physician or health care worker.

8. The method of claim 1 , wherein the maximum daily dose of the cetirizine or levocetirizine provides a highest no observable adverse effect level of the cetirizine or levocetirizine.

9. The method of claim 1 , wherein the human subject is not responding to the maximum daily dose.

Assignments (5)
RELEASE OF INTELLECTUAL PROPERTY SECURITY AGREEMENTS AT R/F 63216/0020 Recorded May 13, 2026
From: ANTARES CAPITAL LP
To: JDP THERAPEUTICS LLC
Reel/Frame 075572/0854 →
RELEASE OF SECOND LIEN PATENT SECURITY AGREEMENT RECORDED AT R/F 063227/0713 Recorded Jan 8, 2025
From: NEWSTONE CAPITAL PARTNERS, LLC
To: JDP THERAPEUTICS LLC
Reel/Frame 069840/0419 →
SECURITY INTEREST Recorded Apr 5, 2023
From: JDP THERAPEUTICS LLC
To: NEWSTONE CAPITAL PARTNERS, LLC
Reel/Frame 063227/0713 →
SECURITY INTEREST Recorded Apr 4, 2023
From: JDP THERAPEUTICS LLC
To: ANTARES CAPITAL LP, AS AGENT
Reel/Frame 063216/0020 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 10, 2019
From: DU, JIE
To: JDP THERAPEUTICS LLC
Reel/Frame 050672/0838 →
Continuity (1)
Related Publication 20210100792A1 · Apr 8, 2021
Cited By (1)
US 12,268,685